PBAC's latest decision on Octreotide: Recommended with restriction (2019). Considered for Treatment of non-functional neuroendocrine tumours of midgut or suspected midgut origin, WHO grade 1 or 2, unresectable locally advanced or metastatic disease.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2018
Submissions
2
2018 → 2019
Eligible population
Adults aged 18 years or older with non-functional neuroendocrine tumours of midgut or suspected midgut origin, WHO grade 1 or 2, unresectable locally advanced or metastatic disease.
Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
PFS
Pivotal trial size
85 patients
Key trials
PROMID, CLARINET
Comparator
lanreotide
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. Submission was on a cost-minimisation basis comparing octreotide with lanreotide.
Risk sharing
Risk-sharing arrangement in place — Special Pricing Arrangement proposed with a confidential rebate on the DPMQ for the new non-functional midgut NETs restriction.
Submission history
Jul 2018: Recommended with restriction · Authority Required
Jul 2019: Recommended with restriction · Authority Required